6-(1-哌嗪基)-3-吡啶胺 | 119285-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 6-(1-哌嗪基)-3-吡啶胺
• 英文名称: 6-(piperazin-1-yl)pyridin-3-amine
• 英文别名: 6-piperazin-1-ylpyridin-3-amine
• CAS: 119285-06-2
• 化学式: C₉H₁₄N₄
• 分子量: 178.237
• InChiKey: MPEVPWUEDJNVHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  54.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(1-哌嗪基)-3-吡啶胺 在 palladium on activated charcoal 正丁基锂 、 sodium azide 、 氢气 、 sodium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 46.5h， 生成 N-((S)-3-{6-[4-(4-Amino-benzenesulfonyl)-piperazin-1-yl]-pyridin-3-yl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide
  参考文献：
  名称：

  Syntheses and antibacterial activity of a series of 3-(pyridine-3-yl)-2-oxazolidinone

  摘要：

  The syntheses of substituted piperazinyl pyridyl oxazolidinones 8-16 are described. Their in vitro activities against Gram-positive organisms such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus and enterococcus were evaluated by minimum inhibitory concentration (MIC) determination. Compound 8 and 10 were found to be superior to linezolid. (C) 2005 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2004.10.012
• 作为产物：
  描述：

  2-溴-5-硝基吡啶 在 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 20.0~150.0 ℃ 、100.0 kPa 条件下， 反应 2.75h， 生成 6-(1-哌嗪基)-3-吡啶胺
  参考文献：
  名称：

  Synthesis and solid state study of pyridine- and pyrimidine-based fragment libraries

  摘要：

  A library of pyridines and pyrimidines has been synthesised in excellent yields employing microwave and flow chemistry methodologies. Work-up bottlenecks have been facilitated substantially by the use of supported reagents and many of the final compounds have been studied in the solid state by single crystal X-ray diffraction. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.07.147

文献信息

• [EN] 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PYRIDINE 2,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE TGF-BÊTA ET PROCÉDÉS D'UTILISATION
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2015157093A1

  公开（公告）日：2015-10-15

  The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.

  本发明涉及的化合物包括公式（IV）的化合物，以及一种治疗癌症的方法，包括向患有癌症的受试者施用其中一种化合物，结合另一种癌症治疗方法。这些化合物（IV）抑制TGF-β超家族成员如Nodal或Activin的信号传导。
• INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
  申请人：Bolin David Robert

  公开号：US20100145047A1

  公开（公告）日：2010-06-10

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供的是式(I)的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如肥胖、2型糖尿病和代谢综合征等疾病是有用的。
• Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors
  申请人：——

  公开号：US20040009988A1

  公开（公告）日：2004-01-15

  The present invention relates to A compound of formula (I) wherein A, U, V, X, Z, R 1 , Y, R 2 and R 3 are defined in the description or a physiologically acceptable salt, solvate or derivative thereof, to compositions and processes for making said compounds and their use in treating conditions ameliorated by an apoB-100 and/or MTP inhibitor. 1

  本发明涉及一种化合物，其化学式为（I），其中A、U、V、X、Z、R1、Y、R2和R3在说明中有定义，或其生理上可接受的盐、溶剂或衍生物，以及制备所述化合物的组合物和方法，以及它们在治疗由apoB-100和/或MTP抑制剂改善的状况中的应用。
• Synthesis and Antibacterial Activities of Eperezolid Analogs with Glycinyl Substitutions
  作者：Xiao-Jun Wang、Ning Wu、Guang-Jian Du、Shuang-Qi Zhao、Ming Yan、Lian-Quan Gu

  DOI：10.1002/ardp.200800233

  日期：2009.7

  A series of eperezolid analogs with glycinyl substitutions were prepared and their antibacterial activities were studied against a panel of susceptible and resistant Gram‐positive bacteria. The compounds with N‐arylacyl or N‐heteroarylacyl glycinyl structural units showed good antibacterial activities. The compounds 11b, 11c, and 11e were twofold more active than linezolid against Staphylococcus epidermidis

  制备了一系列具有甘氨酰基取代的 eperezolid 类似物，并研究了它们对一组敏感和耐药革兰氏阳性细菌的抗菌活性。具有N-芳酰基或N-杂芳酰基甘氨酰基结构单元的化合物表现出良好的抗菌活性。化合物 11b、11c 和 11e 对表皮葡萄球菌和粪肠球菌的活性是利奈唑胺的两倍。还制备了几种吡啶类似物，发现对大多数测试的革兰氏阳性细菌的抗菌活性较差，但是，其中一种化合物 12e 对粪肠球菌表现出非常高的活性。
• [EN] CYCLIN-DEPENDENT KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES DÉPENDANTES DES CYCLINES
  申请人：SPV THERAPEUTICS INC

  公开号：WO2020140053A1

  公开（公告）日：2020-07-02

  Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

  本文描述了化合物及其药用可接受的盐、药物组合物、治疗方法和医疗用途。本文描述的化合物是细胞周期依赖性激酶的调节剂，可用于治疗或缓解与蛋白激酶相关的疾病，包括癌症、传染病、自身免疫疾病或心血管疾病。